1859, an AI-based small molecule drug discovery company advancing next generation medicines, is pleased to announce the appointment of Sanket Agrawal as its Chief Executive Officer , effective April 2023. As an experienced biopharma business leader, Agrawal joins 1859 to drive its next stage of growth and deliver on the company’s potential to rapidly discover superior molecules. The company has demonstrated its discovery engine capabilities through more than 15 partnerships with pharmaceutical, biotech, and academic organizations, yielding novel small molecule compound designs for multiple targets.